摘要
目的探讨β-微管蛋白Ⅲ(TUBB3)和胸苷酸合成酶(TYMS)mRNA在进展期食管胃交界部腺癌(AEGJ)组织中的表达情况及在XP方案新辅助化疗疗效预测中的价值。方法 54例进展期AEGJ患者均行XP方案化疗,并评价疗效。用分支DNA-液相芯片技术检测TUBB3、TYMS mRNA的表达情况,分析各基因表达与化疗疗效的关系。结果 54例患者新辅助化疗有效率为48.15%。TUBB3、TYMS mRNA的低表达率分别18.52%%和25.93%;TUBB3、TYMS mRNA的表达与化疗敏感性有关。结论 TUBB3、TYMS mRNA低表达是XP方案新辅助化疗敏感性的影响因素,两者的表达情况可为AEGJ个体化新辅助化疗方案的选择提供有益的参考。
Objective To investigate the expressions of TUBB3,TYMS mRNA in the locally advanced adenoearcinoma of esophagogastric junction（AEGJ） and the relationship with efficacy of neoadjuvant chemotherapy. Methotis The 54 patients with locally advanced AEGJ were given with XP neoadjuvant chemotherapy regimen, and the efficacy were evaluated. The expressions of TUBB3, TYMS mRNA were detected by multiplex branched-DNA liquid chip technology in all the patients before neoadjuvant chemotherapy. The relationship between various genes and chemotherapy efficacy was analyzed by univariate and logistic multivariate regression analyses. Results The overall response rates was 48.15%. The low expression rate of TUBB3, TYMS mRNA in the locally advanced AEGJ was 18.52% and 25.93%. Low expressions of TUBB3 ,TYMS mRNA were seen as risk factors for drug-resistance. Con- clusion Low expressions of TUBB3 ,TYMS mRNA are important factors for XP regimen insensitivity in the locally advanced AEGJ. They may provide an useful reference for designing individualized chemotherapeutic regimens for patients with locally advanced AEGJ.
出处
《肿瘤基础与临床》
2016年第4期304-308,共5页
journal of basic and clinical oncology
基金
河南省科技发展计划重点攻关项目(编号:112102310121)
